Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy

Neurological Research

Volumn 34, Issue 8, 2012, Pages 738-745

  Minagar, Alireza ^a   Maghzi, Amir H ^b   Mcgee, Jeanie C ^a   Alexander, Steven J ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Cytokine; Endothelium; MRI; Multiple sclerosis

Indexed keywords

MYELIN; NATALIZUMAB; RECOMBINANT GAMMA INTERFERON;

APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CELL STRESS; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; DIAPEDESIS; DISEASE ACTIVITY; DRUG DOSE COMPARISON; DRUG TARGETING; ENDOTHELIUM CELL; EXTRAVASATION; HUMAN; IMMUNOSURVEILLANCE; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION;

ADJUVANTS, IMMUNOLOGIC; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CELL MIGRATION INHIBITION; ENDOTHELIAL CELLS; HUMANS; LEUKOCYTES; MULTIPLE SCLEROSIS;

EID: 84866232930     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132812Y.0000000072     Document Type: Article

References (86)

1. Redzic Z. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS. 2011;8:3.
2. Engelhardt B. Neuroscience. Blood-brain barrier differentiation. Science. 2011;334:1652-1653.
3. Dohgu S, Takata F, Yamauchi A, Nakagawa S, Egawa T, Naito M, et al. Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-beta production. Brain Res. 2005;1038:208-215.
4. Shimizu F, Sano Y, Saito K, Abe MA, Maeda T, Haruki H, et al. Pericyte-derived glial cell line-derived neurotrophic factor increase the expression of claudin-5 in the blood-brain barrier and the blood-nerve barrier. Neurochem Res. 2012;37:401-409.
5. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, et al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol. 1993;123:1777-1788.
6. Wilhelm I, Fazakas C, Krizbai IA. In vitro models of the blood-brain barrier. Acta Neurobiol Exp (Wars). 2011;71(1):113-128.
7. Blaschuk OW, Oshima T, Gour BJ, et al. Identification of an occludin cell adhesion recognition sequence, Inflammation. 2002;26:193-198.
8. Oshima T, Blaschuk O, Gour B, Symonds M, Elrod JW, Sasaki M, et al. Tight junction peptide antagonists enhance neutrophil trans-endothelial chemotaxis. Life Sci. 2003;73:1729-1740.
9. Alexander JS, Dayton T, Davis C, Hill S, Jackson TH, Blaschuk O, et al. Activated T-lymphocytes express occludin, a component of tight junctions, Inflammation. 1998;22:573-582.
10. Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol. 2003;81:1-44.
11. Kevil CG, Okayama N, Trocha SD, Kalogeris TJ, Coe LL, Specian RD, et al. Expression of zonula occludens and adherens junctional proteins in human venous and arterial endothelial cells: role of occludin in endothelial solute barriers. Microcirculation. 1998;5:197-210.
12. Kevil CG, Oshima T, Alexander B, Coe LL, Alexander JS. H2O2-mediated permeability: role of MAPK and occludin. Am J Physiol Cell Physiol. 2000;279:C21-C30.
13. Kevil CG, Oshima T, Alexander JS. The role of p38 MAP kinase in hydrogen peroxide mediated endothelial solute permeability. Endothelium. 2001;8:107-116.
14. Dejana E, Zanetti A, Del MA. Adhesive proteins at endothelial cell-to-cell junctions and leukocyte extravasation. Haemostasis. 1996;26(Suppl 4):210-219.
15. Kevil CG, Payne DK, Mire E, Alexander JS. Vascular permeability factor/vascular endothelial cell growth factormediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem. 1998;273:15099-15103.
16. Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler. 2003;9:540-549.
17. Minagar A, Long A, Ma T, Jackson TH, Kelley RE, Ostanin DV, et al. Interferon (IFN)-beta 1a and IFN-beta 1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier. Endothelium. 2003;10:299-307.
18. Chaitanya GV, Cromer WE, Wells SR, Jennings MH, Couraud PO, Romero IA, et al. Gliovascular and cytokine interactions modulate brain endothelial barrier in vitro. J Neuroinflammation. 2011;8:162.
19. Beeman NE, Baumgartner HK, Webb PG, Schaack JB, Neville MC. Disruption of occludin function in polarized epithelial cells activates the extrinsic pathway of apoptosis leading to cell extrusion without loss of transepithelial resistance. BMC Cell Biol. 2009;10:85.
20. Haghjooy Javanmard S, Saadatnia M, Homayouni V, Nikoogoftar M, Maghzi AH, Etemadifar M, et al. Interferon-beta-1b protects against multiple sclerosis-induced endothelial cells apoptosis. Front Biosci (Elite Ed). 2012;4:1368-1374.
21. Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci. 2003;206:187-191.
22. Horstman LL, Jy W, Bidot CJ, Nordberg ML, Minagar A, Alexander JS, et al. Potential roles of cell-derived microparticles in ischemic brain disease. Neurol Res. 2009;31:799-806.
23. Chaitanya GV, Cromer W, Wells S, Jennings M, Mathis JM, Minagar A, et al. Metabolic modulation of cytokine-induced brain endothelial adhesion molecule expression. Microcirculation. 2012;19:155-165.
24. Sharp C, Hines I, Houghton J, Warren A, Jackon TH 4th, Jawahar A, et al. Glutamate causes a loss in human cerebral endothelial barrier integrity through activation of NMDA receptor. Am J Physiol Hearth Circ Physiol. 2003;285(6): H2592-H2599.
25. Sharp C, Houghton J, Elrod JW, Warren A, Jackson TH 4th, Jawahar A, et al. N-methyl-D-aspartate receptor activation in human cerebral endothelium promotes intracellular oxidant stress. Am J Physiol Heart Circ Physiol. 2005;288(4):H1893-H1899.
26. Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res. 2007;85:2059-2070.
27. Enerson BE, Drewes LR. The rat blood-brain barrier transcriptome. J Cereb Blood Flow Metab. 2006;26:959-973.
28. Regina A, Morchoisne S, Borson ND, McCall AL, Drewes LR, Roux F. Factor(s) released by glucose-deprived astrocytes enhance glucose transporter expression and activity in rat brain endothelial cells. Biochim Biophys Acta. 2001;1540:233-242.
29. Dore-Duffy P, Balabanov R, Beaumont T, Katar M. The CNS pericyte response to low oxygen: early synthesis of cyclopentenone prostaglandins of the J-series. Microvasc Res. 2005;69:79-88.
30. Mooradian AD, Chung HC, Shah GN. GLUT-1 expression in the cerebra of patients with Alzheimer's disease. Neurobiol Aging. 1997;18:469-474.
31. Zheng PP, Romme E, van der Spek PJ, Dirven CM, Willemsen R, Kros JM. Glut1/SLC2A1 is crucial for the development of the blood-brain barrier in vivo. Ann Neurol. 2010;68:835-844.
32. Lowery-Nordberg M, Eaton E, Gonzalez-Toledo E, Harris MK, Chalamidas K, McGee-Brown J, et al. The effects of high dose interferon-beta1a on plasma microparticles: correlation with MRI parameters. J Neuroinflammation. 2011;8:43.
33. Sheremata WA, Jy W, Horstman LL, Ahn YS, Alexander JS, Minagar A. Evidence of platelet activation in multiple sclerosis. J Neuroinflammation. 2008;5:27.
34. Jimenez J, Jy W, Mauro LM, Horstman LL, Ahn ER, Ahn YS, et al. Elevated endothelial microparticle-monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-beta 1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes. Mult Scler. 2005;11:310-315.
35. Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, et al. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol. 2008;65:199-204.
36. Alexander JS, Harris MK, Wells SR, Mills G, Chalamidas K, Ganta VC, et al. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler. 2010;16:801-809.
37. Benesova Y, Vasku A, Stourac P, Hladikova M, Beranek M, Kadanka Z, et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis. J Neuroimmunol. 2008;205:105-109.
38. Hasty KA, Pourmotabbed TF, Goldberg GI, Thompson JP, Spinella DG, Stevens RM, et al. Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. J Biol Chem. 1990;265:11421-11424.
39. Naegele M, Tillack K, Reinhardt S, Schippling S, Martin R, Sospedra M. Neutrophils in multiple sclerosis are characterized by a primed phenotype. J Neuroimmunol. 2012;242:60-71.
40. Liu L, Belkadi A, Darnall L, Hu T, Drescher C, Cotleur AC, et al. CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis, Nat Neurosci. 2010;13:319-326.
41. Wachtel M, Frei K, Ehler E, Fontana A, Winterhalter K, Gloor SM. Occludin proteolysis and increased permeability in endothelial cells through tyrosine phosphatase inhibition. J Cell Sci. 1999;112(Pt 23):4347-4356.
42. Alexander JS, Elrod JW. Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation. J Anat. 2002;200:561-574.
43. Bauer AT, Burgers HF, Rabie T, Marti HH. Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J Cereb Blood Flow Metab. 2010;30:837-848.
44. Nelissen I, Martens E, van den Steen PE, Proost P, Ronsse I, Opdenakker G. Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy. Brain. 2003;126:1371-1381.
45. Comini-Frota ER, Rodrigues DH, Miranda EC, Brum DG, Kaimen-Maciel DR, Donadi EA, et al. Serum levels of brain-derived neurotrophic factor correlate with the number of T2 MRI lesions in multiple sclerosis. Braz J Med Biol Res. 2012;45:68-71.
46. Stuve O, Chabot S, Jung SS, Williams G, Yong VW. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. J Neuroimmunol. 1997;80:38-46.
47. Opdenakker G, Van DJ. Probing cytokines, chemokines and matrix metalloproteinases towards better immunotherapies of multiple sclerosis. Cytokine Growth Factor Rev. 2011;22:359-365.
48. Agrawal SM, Silva C, Tourtellotte WW, Yong VW. EMMPRIN: a novel regulator of leukocyte transmigration into the CNS in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci. 2011;31:669-677.
49. Festa ED, Hankiewicz K, Kim S, Skurnick J, Wolansky LJ, Cook SD, et al. Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult Scler. 2009;15:1271-1279.
50. Weiss N, Deboux C, Chaverot N, Miller F, Baron-Van EA, Couraud PO, et al. IL8 and CXCL13 are potent chemokines for the recruitment of human neural precursor cells across brain endothelial cells. J Neuroimmunol. 2010;223:131-134.
51. Martins T, Rose JW, Jaskowski TD, Wilson AR, Husebye D, Seraj HS, et al. Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am J Clin Pathol. 2011;136(5):696-704.
52. Alatab S, Maghbooli Z, Hossein-Nezhad A, Khosrofar M, Mokhtari F. Cytokine profile, Foxp3 and nuclear factor-KB ligand levels in multiple sclerosis subtypes. Minerva Med. 2011;102:461-468.
53. Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther. 2010;10:587-604.
54. Iarlori C, Reale M, Lugaresi A, De LG, Bonanni L, Di IA, et al. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b. J Neuroimmunol. 2000;107:100-107.
55. Mishra M, Kumar H, Bajpai S, Singh RK, Tripathi K. Level of serum IL-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed type 2 diabetes. Diabetes Res Clin Pract. 2011;94(2):255-261.
56. Sorensen EW, Gerber SA, Frelinger JG, Lord EM. IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. J Immunol. 2010;184:1858-1866.
57. Jones JL, Coles AL. New treatment strategies in multiple sclerosis. Exp Neurol. 2010;225:34-39.
58. Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology. 2002;59:990-997.
59. Wang J, Xiao Y, Luo M, Zhang X, Luo H. Statins for multiple sclerosis. Cochrane Database Syst Rev. 2010;12:CD008386.
60. Weinstock-Guttman B, Zivadinov R, Mahfooz N, Carl E, Drake A, Schneider J, et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation. 2001;8:127.
61. Sasaki M, Bharwani S, Jordan P, Elrod JW, Grisham MB, Jackson TH, et al. Increased disease activity in eNOS-deficient mice in experimental colitis. Free Radic.Biol Med. 2003;35:1679-1687.
62. Sasaki M, Bharwani S, Jordan P, Joh T, Manas K, Warren A, et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis, J Pharmacol Exp Ther. 2003;305:78-85.
63. Desai LP, White SR, Waters CM. Mechanical stretch decreases FAK phosphorylation and reduces cell migration through loss of JIP3-induced JNK phosphorylation in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2009;297:L520-L259.
64. Ghosh BC, Shatzkes J, Webb H. Primary epiploic appendagitis: diagnosis, management, and natural course of the disease. Mil Med. 2003;168:346-347.
65. Hellwig K, Gold R. Progressive multifocal leukoencephalopathy and natalizumab. J Neurol. 2011;258:1920-1928.
66. Streeter PR, Berg EL, Rouse BT, Bargatze RT, Butcher EC. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature. 1988;331:41-46.
67. Yang Y, Cardarelli PM, Lehnert K, Rowland S, Krissansen GW. LPAM-1 (integrin alpha 4 beta 7)-ligand binding: overlapping binding sites recognizing VCAM-1, MAdCAM-1 and CS-1 are blocked by fibrinogen, a fibronectin-like polymer and RGD-like cyclic peptides. Eur J Immunol. 1998;28:995-1004.
68. Berger JR, Khalili K. The pathogenesis of progressive multifocal leukoencephalopathy. Discov Med. 2011;12:495-503.
69. Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol. 2006;63:614-619.
70. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci. 2006;27:48-55.
71. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity, Ann.Neurol. 1995;37:82-88.
72. Oshima T, Laroux FS, Coe LL, Morise Z, Kawachi S, Bauer P, et al. Interferon-gamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function. Microvasc Res. 2001;61:130-143.
73. Plumb J, McQuaid S, Cross AK, Surr J, Haddock G, Bunning, RA, et al. Upregulation of ADAM-17 expression in active lesions in multiple sclerosis. Mult Scler. 2006;12:375-385.
74. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 1988;23: 339-346.
75. Enayati PJ, Papadakis KA. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol. 2005;39:303-306.
76. Naylor SL, Sakaguchi AY, Shows TB, Law ML, Goeddel DV, Gray PW. Human immune interferon gene is located on chromosome 12. J Exp Med. 1983;157:1020-1027.
77. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41-101.
78. Ealick SE, Cook WJ, Vijay-Kumar S, Carson M, Nagabhushan TL, Trotta PP, et al. Three-dimensional structure of recombinant human interferon-gamma. Science. 1991;252:698-702.
79. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand. 1988;78:318-323.
80. Lu CZ, Jensen MA, Arnason BG. Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol. 1993;46:123-128.
81. Woodroofe MN, Cuzner ML. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine. 1993;5: 583-588.
82. Bitsch A, Kuhlmann T, Da CC, Bunkowski S, Polak T, Bruck W. Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia. 2000;29:366-375.
83. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987;37:1097-1102.
84. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987;1:893-895.
85. Billiau A, Heremans H, Vermeire K, Matthys P. Immunomodulatory properties of interferon-gamma. An update. Ann NY Acad Sci. 1998;856:22-32.
86. Duong TT, St LJ, Gilbert JJ, Finkelman FD, Strejan GH. Effect of anti-interferon-gamma and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse. J Neuroimmunol. 1992;36:105-115.